|Institutional Source||Beutler Lab|
|Is this an essential gene?||Non essential (E-score: 0.000)|
|Stock #||R7013 (G1)|
|Chromosomal Location||121635376-121679227 bp(+) (GRCm38)|
|Type of Mutation||missense|
|DNA Base Change (assembly)||A to G at 121641386 bp|
|Amino Acid Change||Isoleucine to Valine at position 213 (I213V)|
|Ref Sequence||ENSEMBL: ENSMUSP00000032203 (fasta)|
|Gene Model||predicted gene model for transcript(s): [ENSMUST00000032203] [ENSMUST00000204850]|
|Predicted Effect||probably null
AA Change: I213V
PolyPhen 2 Score 0.001 (Sensitivity: 0.99; Specificity: 0.15)
AA Change: I213V
|Predicted Effect||probably benign
|Coding Region Coverage||
|Validation Efficiency||100% (47/47)|
|MGI Phenotype||FUNCTION: [Summary is not available for the mouse gene. This summary is for the human ortholog.] The protein encoded by this gene is a protease inhibitor and cytokine transporter. It uses a bait-and-trap mechanism to inhibit a broad spectrum of proteases, including trypsin, thrombin and collagenase. It can also inhibit inflammatory cytokines, and it thus disrupts inflammatory cascades. Mutations in this gene are a cause of alpha-2-macroglobulin deficiency. This gene is implicated in Alzheimer's disease (AD) due to its ability to mediate the clearance and degradation of A-beta, the major component of beta-amyloid deposits. A related pseudogene, which is also located on the p arm of chromosome 12, has been identified. [provided by RefSeq, Nov 2016]|
|Allele List at MGI|
|Other mutations in this stock||
|Other mutations in A2m||
(F):5'- ATGGATGGCTGGAACTCACC -3'
(R):5'- GCCCCACTGGACTTTTATGTAATTAG -3'
(F):5'- CTTTATGGGTAACATGGAAGTTTCC -3'
(R):5'- AGTTCTACTCTGAGCTTGAAACC -3'